Women’s Health Isn’t a Niche – It’s a Growth Market
When you hear “women’s health”, what comes to mind?
For years, the industry answer has been predictable: maternity, fertility, breast cancer. Important areas, of course. But nowhere near the full picture.
This International Women’s Day, it’s worth looking at the data. Because the numbers tell a very clear story.
Women represent nearly half of the global population, yet only around 6% of private healthcare investment is directed toward women’s health. Companies exclusively focused on women’s health receive less than 1% of total healthcare funding.
That’s not a small market. That’s structural underinvestment.
A $100 Billion Opportunity Hiding in Plain Sight
The imbalance becomes even clearer when you look beyond reproductive health.
Today, around 90% of investment in women’s health is concentrated in reproductive health, maternal health and oncology. Meanwhile, conditions such as cardiovascular disease, osteoporosis, menopause and Alzheimer’s in women remain significantly underfunded.
Addressing just these four areas could unlock more than $100 billion in market potential by 2030.
Women live longer than men, but spend 25% more time in poor health or with disability. That has implications not just for healthcare systems, but for workforce participation, productivity and long-term economic growth.
Women’s health isn’t just a social conversation – it’s also a commercial one.
Resilient Through the Downturn
If women’s health was truly a “niche”, we’d expect it to shrink first during market turbulence.
The opposite happened:
Between 2022 and 2023, overall health tech venture funding dropped by 27%. Investment into women’s health innovators grew by 5% over the same period. That’s a 32-percentage-point difference.
Yet women’s health still represented only 2% of total health venture funding in 2023.
So yes, momentum is building – but the funding gap remains significant.
At the same time, the ecosystem is expanding rapidly. Over the past decade, the number of women’s health-focused businesses has increased by 1,000%, with more than 60% founded in the six years leading up to 2022.
So, Innovation isn’t the issue. Scaling is.
The Scaling Gap
Around half of women’s health investments take place at pre-seed or seed stage (WEF 2026). Early innovation is strong. But moving from early-stage breakthrough to global commercial success is where many companies face challenges.
We’ve seen that scale is possible. The IVF segment demonstrates that when science, reimbursement and regulation align, women’s health can become a multi-billion-dollar industry. Larger M&A and private equity transactions also show that pharma and medtech players are increasingly viewing women’s health as a strategic asset class.
It’s Not Just an R&D Problem
Women drive 80% of healthcare decisions in the US. Yet only 4% of US research spend is targeted specifically toward women’s health.
Additonally, only 34% of US medical students report feeling equipped to address sex and gender differences in care.
This is a capability gap as much as a capital gap.
Progress requires:
- Clinical trials designed with sex-specific endpoints
- Stronger real-world evidence and data infrastructure
- Modernised regulatory frameworks and expanded reimbursement pathways
- Digital health platforms, wearables and AI-enabled diagnostics tailored to women
- Strategic M&A and ecosystem consolidation
Women’s health sits at the intersection of biopharma, medtech, diagnostics and digital health. It’s no longer a subcategory, it’s a cross-sector growth area.
What This Means for Hiring and Talent
As capital begins to diversify into cardiovascular, neurology, metabolic and longevity-focused solutions for women, companies will need specialist expertise to support that growth.
That includes:
- Regulatory affairs and market access professionals navigating evolving coding and reimbursement landscapes
- Clinical development leaders with experience in inclusive trial design
- Health economics and outcomes specialists
- AI, data and digital health engineers building secure and compliant platforms
- Commercial leaders capable of scaling early-stage innovation globally
- M&A and integration talent as consolidation increases
An early-stage-heavy market creates a scaling gap. Bridging that gap requires experienced leadership and technical specialists who understand both the science and the commercial reality.
This is where recruitment becomes strategic:
At Amoria Bond, we work exclusively across specialist Technology, Energy and Advanced Engineering markets, including Life Sciences. As women’s health transitions from overlooked category to strategic growth pillar, we’re seeing increased demand for highly specialised regulatory, R&D, digital and commercial talent across North America and Europe.
For organisations building dedicated women’s health portfolios or expanding existing pipelines, hiring the right expertise early can determine how quickly — and how successfully — they scale.
Time to Act
Women make up half the population – yet their health remains structurally underfunded. The data is clear: women’s health isn’t a niche, it’s one of the largest untapped opportunities in healthcare. Innovation is happening, demand is rising, and investors are beginning to pay attention – now it’s time to turn momentum into impact.
Companies that invest early in expertise, scalable solutions, and the right talent won’t just drive meaningful change – they’ll gain a strategic advantage in a market poised for exponential growth. The future of women’s health is being written now, and those who act decisively will lead the way.
Ready to build (out) your Life Sciences team? Get in touch with us today to find the right talent to scale your impact.
Sources
https://www.weforum.org/publications/women-s-health-investment-outlook-2026/
https://www.bcg.com/press/20january2026-private-healthcare-investment-womens-health